Plain-English translation of NCT05636540 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This early-phase study is testing a new imaging scan called 18F-FluorThanatrace PET/CT to help doctors see and measure tumor activity in patients with pheochromocytoma or paraganglioma—rare tumors that produce excess hormones. The scan works by injecting a small amount of radioactive tracer into your bloodstream, which highlights areas where the tumor is active so doctors can see them more clearly. Researchers hope this new imaging tool will help them better understand these tumors and guide treatment decisions.
Current imaging methods don't always show all the details doctors need to fully understand these rare tumors or predict how they will respond to treatment. This new scan may provide better information to help doctors choose the most effective treatment for each patient.
You likely qualify if…
You likely don't qualify if…
You will receive an injection of the radioactive tracer and then undergo two imaging scans—one starting right after the injection and another about 90 minutes later—with each scan taking about 60 minutes and covering your head to thigh. If you have surgery as part of your standard care, tissue samples may be collected for research. If you are receiving chemotherapy or radiation therapy, you may be asked to return for an optional second scan within 1–3 weeks after starting treatment to see how the tumor has changed.
AI-generated summary from trial data · Aug 20, 2026 · Not medical advice
United States